The translational revolution and use of biologics in patients with inflammatory skin diseases.

[1]  C. Leonardi,et al.  Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis. , 2015, The Journal of allergy and clinical immunology.

[2]  D. Shrom,et al.  IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. , 2014, The Journal of investigative dermatology.

[3]  G. Yancopoulos,et al.  Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[4]  B. Strober,et al.  Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. , 2014, The American journal of medicine.

[5]  J. Silverberg,et al.  Efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States. , 2014, JAMA dermatology.

[6]  Masutaka Furue,et al.  The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. , 2014, The Journal of allergy and clinical immunology.

[7]  E. Sprecher,et al.  Peeling off the genetics of atopic dermatitis-like congenital disorders. , 2014, The Journal of allergy and clinical immunology.

[8]  D. Leung,et al.  Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum. , 2014, The Journal of allergy and clinical immunology.

[9]  P. Elias,et al.  Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[10]  D. Leung,et al.  Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. , 2014, The Journal of allergy and clinical immunology.

[11]  S. Kežić,et al.  Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[12]  V. Chandran,et al.  Biomarkers in Psoriatic Arthritis: Recent Progress , 2014, Current Rheumatology Reports.

[13]  M. Kubo,et al.  IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. , 2014, The Journal of investigative dermatology.

[14]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. , 2014, Journal of the American Academy of Dermatology.

[15]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[16]  Fabian J Theis,et al.  Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema , 2014, Science Translational Medicine.

[17]  T. Bieber,et al.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.

[18]  J. Bouwstra,et al.  TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. , 2014, The Journal of investigative dermatology.

[19]  M. Suárez-Fariñas,et al.  Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. , 2014, The Journal of allergy and clinical immunology.

[20]  A. Armstrong,et al.  JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis , 2014, Journal of immunology research.

[21]  J. Silverberg,et al.  Associations of Childhood Eczema Severity: A US Population-Based Study , 2014, Dermatitis : contact, atopic, occupational, drug.

[22]  Hugh A. Rand,et al.  Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody , 2014, The Journal of Immunology.

[23]  G. D'Amato,et al.  Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review , 2014, Multidisciplinary Respiratory Medicine.

[24]  S. Wenzel,et al.  Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. , 2014, The Journal of allergy and clinical immunology.

[25]  Y. Wasfi,et al.  Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. , 2014, The Journal of allergy and clinical immunology.

[26]  M. Akiyama,et al.  Comprehensive screening for a complete set of Japanese‐population‐specific filaggrin gene mutations , 2014, Allergy.

[27]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[28]  D. Gladman,et al.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.

[29]  D. Margolis,et al.  Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. , 2014, The Journal of allergy and clinical immunology.

[30]  K. Hartmann,et al.  Interleukin-31: A Novel Diagnostic Marker of Allergic Diseases , 2014, Current Allergy and Asthma Reports.

[31]  J. Schmitt,et al.  Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. , 2014, The Journal of allergy and clinical immunology.

[32]  A. Montanaro,et al.  Biologic targeted therapy in allergic asthma. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[33]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. , 2014, Journal of the American Academy of Dermatology.

[34]  T. Illig,et al.  Increased efficacy of omalizumab in atopic dermatitis patients with wild‐type filaggrin status and higher serum levels of phosphatidylcholines , 2014, Allergy.

[35]  C. Flohr,et al.  New insights into the epidemiology of childhood atopic dermatitis , 2014, Allergy.

[36]  D. Schoenfeld,et al.  Alefacept Promotes Immunosuppression‐Free Renal Allograft Survival in Nonhuman Primates via Depletion of Recipient Memory T Cells , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  A. Hatami,et al.  Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. , 2013, Journal of the American Academy of Dermatology.

[38]  D. Margolis,et al.  Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. , 2013, JAMA dermatology.

[39]  M. Raftery,et al.  IL-29 Is Produced by TH17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis , 2013, Science Translational Medicine.

[40]  S. Mosesova,et al.  Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. , 2013, The Journal of allergy and clinical immunology.

[41]  V. Fischetti,et al.  Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases. , 2013, The Journal of allergy and clinical immunology.

[42]  A. Gottlieb,et al.  Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. , 2013, Journal of drugs in dermatology : JDD.

[43]  M. Suárez-Fariñas,et al.  Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. , 2013, The Journal of allergy and clinical immunology.

[44]  J. Krueger,et al.  IL-17 targeted therapies for psoriasis , 2013, Expert opinion on investigational drugs.

[45]  S. Mun,et al.  Anti‐immunoglobulin E in the treatment of refractory atopic dermatitis , 2013, Clinical and experimental dermatology.

[46]  K. Nadeau,et al.  Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial , 2013, International Archives of Allergy and Immunology.

[47]  P. Kuna,et al.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. , 2013, The Journal of allergy and clinical immunology.

[48]  S. Wenzel,et al.  Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.

[49]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[50]  J. Krueger,et al.  Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. , 2013, The Journal of allergy and clinical immunology.

[51]  Rosa Parisi,et al.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence. , 2013, The Journal of investigative dermatology.

[52]  K. Dyer,et al.  Eosinophils: changing perspectives in health and disease , 2012, Nature Reviews Immunology.

[53]  S. Feldman,et al.  Comparative Efficacy of Biologics in Psoriasis , 2012, American Journal of Clinical Dermatology.

[54]  J. Krueger.  Hiding under the skin: A welcome surprise in psoriasis , 2012, Nature Medicine.

[55]  F. Horak,et al.  The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial , 2012, Allergy.

[56]  M. Suárez-Fariñas,et al.  Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. , 2012, The Journal of allergy and clinical immunology.

[57]  A. Vatrella,et al.  The potential of biologics for the treatment of asthma , 2012, Nature Reviews Drug Discovery.

[58]  G. Imokawa,et al.  Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: an implication for the disrupted barrier mechanism in atopic dermatitis. , 2012, Journal of dermatological science.

[59]  D. Margolis,et al.  The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. , 2012, The Journal of allergy and clinical immunology.

[60]  A. Paller,et al.  Understanding and managing atopic dermatitis in adult patients. , 2012, Seminars in cutaneous medicine and surgery.

[61]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[62]  J. O’Shea,et al.  Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. , 2012, Current opinion in pharmacology.

[63]  F. Kerdel,et al.  The use of cyclosporine in dermatology. , 2012, Journal of drugs in dermatology : JDD.

[64]  E. Simpson,et al.  A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. , 2012, Archives of dermatology.

[65]  H. Tey,et al.  Atopic Dermatitis in African American Children: Addressing Unmet Needs of a Common Disease , 2012, Pediatric dermatology.

[66]  P. Schafer.  Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. , 2012, Biochemical Pharmacology.

[67]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[68]  J. Ortonne,et al.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. , 2012, The New England journal of medicine.

[69]  K. Reich.  The concept of psoriasis as a systemic inflammation: implications for disease management , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[70]  M. Weichenthal,et al.  Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis , 2012, Allergy.

[71]  B. Lüscher,et al.  IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. , 2012, The Journal of allergy and clinical immunology.

[72]  L. Xue,et al.  Pharmacologic Profile of OC000459, a Potent, Selective, and Orally Active D Prostanoid Receptor 2 Antagonist That Inhibits Mast Cell-Dependent Activation of T Helper 2 Lymphocytes and Eosinophils , 2012, Journal of Pharmacology and Experimental Therapeutics.

[73]  I. Pavord,et al.  A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[74]  David J. Margolis,et al.  Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom , 2011, The Journal of investigative dermatology.

[75]  H. Lin,et al.  Medical comorbidity associated with psoriasis in adults: a population‐based study , 2011, The British journal of dermatology.

[76]  G. D. Dal Pan,et al.  Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. , 2011, Journal of the American Academy of Dermatology.

[77]  J. Carucci,et al.  Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. , 2011, The Journal of allergy and clinical immunology.

[78]  A. Bowcock,et al.  Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. , 2011, The Journal of allergy and clinical immunology.

[79]  P. Hart,et al.  Modulation of the immune system by UV radiation: more than just the effects of vitamin D? , 2011, Nature Reviews Immunology.

[80]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. , 2011, The Journal of allergy and clinical immunology.

[81]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. , 2011, The Journal of allergy and clinical immunology.

[82]  T. Kanda,et al.  Distinct Roles of IL-23 and IL-17 in the Development of Psoriasis-Like Lesions in a Mouse Model , 2011, The Journal of Immunology.

[83]  A. Bowcock,et al.  Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. , 2011, The Journal of allergy and clinical immunology.

[84]  S. Chimenti,et al.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.

[85]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[86]  Lisa C. Zaba,et al.  Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses. , 2010, The Journal of allergy and clinical immunology.

[87]  W. White,et al.  A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. , 2010, Journal of the American Academy of Dermatology.

[88]  K. Asadullah,et al.  The Th17 cytokine IL‐22 induces IL‐20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis , 2009, European journal of immunology.

[89]  Mayte Suárez-Fariñas,et al.  Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. , 2009, The Journal of allergy and clinical immunology.

[90]  Mayte Suárez-Fariñas,et al.  Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. , 2009, The Journal of allergy and clinical immunology.

[91]  M. Weichenthal,et al.  Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. , 2009, The Journal of allergy and clinical immunology.

[92]  H. Volk,et al.  IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not , 2009, Journal of Molecular Medicine.

[93]  J. Gelfand,et al.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. , 2009, Journal of the American Academy of Dermatology.

[94]  J. Carucci,et al.  Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1 , 2008, The Journal of Immunology.

[95]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[96]  J. Redzic,et al.  Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. , 2008, The Journal of investigative dermatology.

[97]  N. Korman,et al.  Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. , 2008, Journal of the American Academy of Dermatology.

[98]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[99]  M. Boguniewicz,et al.  Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. , 2008, Clinical immunology.

[100]  Lisa C. Zaba,et al.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses , 2007, The Journal of experimental medicine.

[101]  Andrea B Troxel,et al.  The risk of mortality in patients with psoriasis: results from a population-based study. , 2007, Archives of dermatology.

[102]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[103]  K. Barnes,et al.  Cytokine modulation of atopic dermatitis filaggrin skin expression. , 2007, The Journal of allergy and clinical immunology.

[104]  Jon M Hanifin,et al.  A Population‐Based Survey of Eczema Prevalence in the United States , 2007, Dermatitis : contact, atopic, occupational, drug.

[105]  J. Carucci,et al.  Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. , 2007, The Journal of allergy and clinical immunology.

[106]  M. Lebwohl,et al.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. , 2007, The New England journal of medicine.

[107]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[108]  Erin G Harper,et al.  Efalizumab for severe atopic dermatitis: a pilot study in adults. , 2007, Journal of the American Academy of Dermatology.

[109]  T. Bieber,et al.  Mechanism of HBD-3 deficiency in atopic dermatitis. , 2006, Clinical immunology.

[110]  T. Zuberbier,et al.  Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. , 2006, The Journal of allergy and clinical immunology.

[111]  R. Strunk,et al.  Omalizumab for asthma. , 2006, The New England journal of medicine.

[112]  K. Asadullah,et al.  IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.

[113]  C. Young,et al.  Narrow-band UVB induces apoptosis in human keratinocytes. , 2006, Journal of photochemistry and photobiology. B, Biology.

[114]  R. Steinman,et al.  Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[115]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[116]  S. Friedlander,et al.  Etanercept is minimally effective in 2 children with atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[117]  J. Ring,et al.  Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis , 2005, Allergy.

[118]  G. Schuler,et al.  Infliximab in the treatment of moderate to severe atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[119]  M. Zaccolo,et al.  TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling1 , 2004, The Journal of Immunology.

[120]  K. Asadullah,et al.  IL-22 increases the innate immunity of tissues. , 2004, Immunity.

[121]  David J Margolis,et al.  Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. , 2004, The journal of investigative dermatology. Symposium proceedings.

[122]  M. Dhodapkar,et al.  Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris , 2004, The Journal of experimental medicine.

[123]  M. Chan-yeung,et al.  Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children , 2003, Genes and Immunity.

[124]  Enzo Berardesca,et al.  Ethnic skin: overview of structure and function. , 2003, Journal of the American Academy of Dermatology.

[125]  M. Mack,et al.  Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease , 2003, Nature Medicine.

[126]  M. van Hage-Hamsten,et al.  Decreased frequency of intracellular IFN‐γ producing T cells in whole blood preparations from patients with atopic dermatitis , 2002, Experimental dermatology.

[127]  H. Suto,et al.  Preferential expression of T(h)2-type chemokine and its receptor in atopic dermatitis. , 2002, International immunology.

[128]  Tomas Ganz,et al.  Endogenous antimicrobial peptides and skin infections in atopic dermatitis. , 2002, The New England journal of medicine.

[129]  A. Gottlieb,et al.  Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. , 2002, Archives of dermatology.

[130]  J. Krueger.  The immunologic basis for the treatment of psoriasis with new biologic agents. , 2002, Journal of the American Academy of Dermatology.

[131]  G. Krueger,et al.  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. , 2001, The New England journal of medicine.

[132]  C. Garbe,et al.  Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. , 2001, The Journal of investigative dermatology.

[133]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[134]  Tae-Yoon Kim,et al.  Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. , 2000, Journal of the American Academy of Dermatology.

[135]  A. Gottlieb,et al.  Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions , 2000 .

[136]  D. Leung,et al.  Atopic dermatitis: new insights and opportunities for therapeutic intervention. , 2000, The Journal of allergy and clinical immunology.

[137]  A. Dorner,et al.  Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. , 1999, The Journal of clinical investigation.

[138]  M. Lebwohl,et al.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. , 1999, The Journal of clinical investigation.

[139]  N. Yawalkar,et al.  Expression of interleukin-12 is increased in psoriatic skin. , 1998, The Journal of investigative dermatology.

[140]  Pirot.,et al.  Differences in stratum corneum pH gradient when comparing white caucasian and black African‐American skin , 1998, The British journal of dermatology.

[141]  A. Gottlieb,et al.  Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells , 1995, The Journal of experimental medicine.

[142]  James G. Krueger,et al.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis , 1995, Nature Genetics.

[143]  A. Gottlieb,et al.  PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy , 1994, The Journal of experimental medicine.

[144]  C. Hsieh,et al.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.

[145]  A. Gottlieb,et al.  Cyclosporine in psoriasis treatment. Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways. , 1991, Archives of dermatology.

[146]  S. Shuster,et al.  Cyclosporin A in atopic dermatitis: therapeutic resonse is disociated form effects on allergic reactons , 1991, The British journal of dermatology.

[147]  A. Gottlieb.  Immunologic mechanisms in psoriasis. , 1990, The Journal of investigative dermatology.

[148]  A. Gottlieb,et al.  Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. , 1990, The Journal of investigative dermatology.

[149]  James T. Elder,et al.  Overexpression of transforming growth factor alpha in psoriatic epidermis. , 1989, Science.

[150]  J. Mansbridge,et al.  Changes in keratinocyte maturation during wound healing. , 1987, The Journal of investigative dermatology.

[151]  L. Nanney,et al.  Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. , 1986, The Journal of investigative dermatology.